Biomarkers for osteoarthritis: Current status and future prospects
Mobasheri, Ali; Thudium, Christian S.; Bay-Jensen, Anne-Christine; Maleitzke, Tazio; Geissler, Sven; Duda, Georg N.; Winkler, Tobias (2023-08-22)
Elsevier
22.08.2023
Mobasheri, A., Thudium, C. S., Bay-Jensen, A.-C., Maleitzke, T., Geissler, S., Duda, G. N., & Winkler, T. (2023). Biomarkers for osteoarthritis: Current status and future prospects. In Best Practice & Research Clinical Rheumatology (Vol. 37, Issue 2, p. 101852). Elsevier BV. https://doi.org/10.1016/j.berh.2023.101852.
https://creativecommons.org/licenses/by/4.0/
© 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
https://creativecommons.org/licenses/by/4.0/
© 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
https://creativecommons.org/licenses/by/4.0/
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:oulu-202401031044
https://urn.fi/URN:NBN:fi:oulu-202401031044
Tiivistelmä
Abstract
Osteoarthritis (OA) is the most common form of arthritis globally and a major cause of pain, physical disability, and loss of economic productivity, with currently no causal treatment available. This review article focuses on current research on OA biomarkers and the potential for using biomarkers in future clinical practice and clinical trials of investigational drugs. We discuss how biomarkers, specifically soluble ones, have a long path to go before reaching clinical standards of care. We also discuss how biomarkers can help in phenotyping and subtyping to achieve enhanced stratification and move toward better-designed clinical trials. We also describe how biomarkers can be used for molecular endotyping and for determining the clinical outcomes of investigational cell-based therapies. Biomarkers have the potential to be developed as surrogate end points in clinical trials and help private-public consortia and the biotechnology and pharmaceutical industries develop more effective and targeted personalized treatments and enhance clinical care for patients with OA.
Osteoarthritis (OA) is the most common form of arthritis globally and a major cause of pain, physical disability, and loss of economic productivity, with currently no causal treatment available. This review article focuses on current research on OA biomarkers and the potential for using biomarkers in future clinical practice and clinical trials of investigational drugs. We discuss how biomarkers, specifically soluble ones, have a long path to go before reaching clinical standards of care. We also discuss how biomarkers can help in phenotyping and subtyping to achieve enhanced stratification and move toward better-designed clinical trials. We also describe how biomarkers can be used for molecular endotyping and for determining the clinical outcomes of investigational cell-based therapies. Biomarkers have the potential to be developed as surrogate end points in clinical trials and help private-public consortia and the biotechnology and pharmaceutical industries develop more effective and targeted personalized treatments and enhance clinical care for patients with OA.
Kokoelmat
- Avoin saatavuus [38824]
Ellei muuten mainita, aineiston lisenssi on https://creativecommons.org/licenses/by/4.0/